NEPHROS, INC. (NEPH) Spending and interest coverage
- R&D / revenue · 12 months: Value 6.97%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.30%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 6.97% | Research and development expense / revenue. Period ending 2026-06-30. $1.45M ÷ $20.72M × 100 ≈ 6.97% |
| Stock-based compensation / revenue · 12 months | 1.30% | Share-based compensation / revenue. Period ending 2026-06-30. $270.00K ÷ $20.72M × 100 ≈ 1.30% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.45M USD | Research and Development Expense |
| Revenue | 20.72M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 270.00K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 1.64M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.45M | $20.72M | $270.00K | $1.64M | (m) | 6.97% | 1.30% | (m) | (m) |
| 2026-03-31 | $1.39M | $19.12M | $280.00K | $677.00K | (m) | 7.27% | 1.46% | (m) | (m) |
| 2025-12-31 | $1.34M | $18.79M | $296.00K | $1.15M | (m) | 7.13% | 1.58% | (m) | (m) |
| 2025-09-30 | $1.20M | $17.93M | $279.00K | $1.45M | (m) | 6.67% | 1.56% | (m) | (m) |
| 2025-06-30 | $1.05M | $16.68M | $274.00K | $1.34M | (m) | 6.27% | 1.64% | (m) | (m) |
| 2025-03-31 | $989.00K | $15.52M | $238.00K | $772.00K | (m) | 6.37% | 1.53% | (m) | (m) |
| 2024-12-31 | $906.00K | $14.16M | $153.00K | $6.00K | (m) | 6.40% | 1.08% | (m) | (m) |
| 2024-09-30 | $862.00K | $13.55M | $481.00K | $-960.00K | (m) | 6.36% | 3.55% | (m) | (m) |
| 2024-06-30 | $879.00K | $13.77M | $565.00K | $-1.37M | (m) | 6.38% | 4.10% | (m) | (m) |
| 2024-03-31 | $846.00K | $14.06M | $724.00K | $-1.49M | $2.00K | 6.02% | 5.15% | -743.50× | Reported |
| 2023-12-31 | $873.00K | $14.24M | $1.05M | $-1.59M | $2.00K | 6.13% | 7.39% | -796.50× | Reported |
| 2023-09-30 | $1.02M | $13.54M | $841.00K | $-1.64M | $4.00K | 7.56% | 6.21% | -409.25× | Reported |
| 2023-06-30 | $1.07M | $12.21M | $946.00K | $-2.71M | $8.00K | 8.76% | 7.75% | -339.38× | Reported |
| 2023-03-31 | $1.12M | $11.51M | $1.03M | $-3.09M | $14.00K | 9.75% | 8.94% | -221.00× | Reported |
| 2022-12-31 | $1.25M | $9.97M | $982.00K | $-4.33M | $20.00K | 12.58% | 9.84% | -216.75× | Reported |
| 2022-09-30 | $1.89M | $10.32M | $1.24M | $-5.45M | $24.00K | 18.34% | 11.99% | -226.92× | Reported |
| 2022-06-30 | $2.13M | $10.47M | $1.25M | $-5.36M | $30.00K | 20.36% | 11.95% | -178.57× | Reported |
| 2022-03-31 | $2.19M | $9.86M | $1.25M | $-5.27M | $35.00K | 22.20% | 12.73% | -150.57× | Reported |
| 2021-12-31 | $2.17M | $10.40M | $1.26M | $-4.33M | $41.00K | 20.82% | 12.10% | -105.73× | Reported |
| 2021-09-30 | $2.28M | $9.97M | $1.03M | $-4.02M | $49.00K | 22.90% | 10.34% | -81.96× | Reported |
| 2021-06-30 | $2.40M | $9.46M | $935.00K | $-3.79M | $61.00K | 25.41% | 9.89% | -62.07× | Reported |
| 2021-03-31 | $2.75M | $8.77M | $833.00K | $-4.27M | $80.00K | 31.39% | 9.50% | -53.34× | Reported |
| 2020-12-31 | $2.76M | $8.56M | $779.00K | $-4.28M | $110.00K | 32.23% | 9.10% | -38.86× | Reported |
| 2020-09-30 | $2.91M | $9.39M | $1.24M | $-3.85M | $150.00K | 31.04% | 13.24% | -25.65× | Reported |
| 2020-06-30 | $2.94M | $10.36M | $1.43M | $-3.61M | $176.00K | 28.37% | 13.75% | -20.51× | Reported |
| 2020-03-31 | $2.90M | $11.09M | $1.40M | $-2.88M | $192.00K | 26.11% | 12.58% | -15.00× | Reported |
| 2019-12-31 | $3.09M | $10.33M | $1.33M | $-3.15M | $195.00K | 29.90% | 12.89% | -16.18× | Reported |
| 2019-09-30 | (m) | $8.79M | $1.06M | $-3.59M | $166.00K | (m) | 12.05% | -21.64× | Reported |
| 2019-06-30 | (m) | $7.41M | $825.00K | $-3.41M | $150.00K | (m) | 11.13% | -22.73× | Reported |
| 2019-03-31 | (m) | $6.47M | $901.00K | $-3.19M | $132.00K | (m) | 13.92% | -24.20× | Reported |
| 2018-12-31 | (m) | $5.69M | $985.00K | $-3.02M | $172.00K | (m) | 17.32% | -17.53× | Reported |
| 2018-09-30 | (m) | $5.38M | $852.00K | $-2.69M | $230.00K | (m) | 15.85% | -11.70× | Reported |
| 2018-06-30 | (m) | $4.57M | $845.00K | $-2.70M | $286.00K | (m) | 18.50% | -9.43× | Reported |
| 2018-03-31 | (m) | $4.06M | $815.00K | $-2.74M | $322.00K | (m) | 20.07% | -8.52× | Reported |
| 2017-12-31 | (m) | $3.81M | $772.00K | $-2.23M | $302.00K | (m) | 20.27% | -7.37× | Reported |
| 2017-09-30 | (m) | $3.25M | $617.00K | $-2.43M | $281.00K | (m) | 18.96% | -8.65× | Reported |
| 2017-06-30 | (m) | $2.81M | $713.00K | $-2.55M | $258.00K | (m) | 25.34% | -9.88× | Reported |
| 2017-03-31 | (m) | $2.46M | $623.00K | $-2.67M | $224.00K | (m) | 25.28% | -11.91× | Reported |
| 2016-12-31 | (m) | $2.32M | $551.00K | $-2.87M | $172.00K | (m) | 23.75% | -16.68× | Reported |
| 2016-09-30 | (m) | $2.09M | (m) | $-3.20M | $121.00K | (m) | (m) | -26.41× | Reported |
| 2016-06-30 | (m) | $1.93M | (m) | $-3.65M | $65.00K | (m) | (m) | -56.11× | Reported |
| 2016-03-31 | (m) | $1.99M | (m) | $-3.42M | $45.00K | (m) | (m) | -76.02× | Reported |
| 2015-12-31 | (m) | $1.94M | (m) | $-3.42M | $42.00K | (m) | (m) | -81.45× | Reported |
| 2015-09-30 | (m) | $1.77M | (m) | $-3.27M | $236.00K | (m) | (m) | -13.88× | Reported |
| 2015-06-30 | (m) | $1.95M | (m) | $-2.87M | $292.00K | (m) | (m) | -9.83× | Reported |
| 2015-03-31 | (m) | $1.82M | (m) | $-2.91M | $299.00K | (m) | (m) | -9.74× | Reported |
| 2014-12-31 | (m) | $1.75M | (m) | $-2.67M | $483.00K | (m) | (m) | -5.53× | Reported |
| 2014-09-30 | (m) | $1.63M | (m) | $-2.95M | $115.00K | (m) | (m) | -25.66× | Reported |
| 2014-06-30 | (m) | $1.56M | (m) | $-2.88M | $117.00K | (m) | (m) | -24.61× | Reported |
| 2014-03-31 | (m) | $1.69M | (m) | $-2.87M | $123.00K | (m) | (m) | -23.34× | Reported |
| 2013-12-31 | (m) | $1.74M | (m) | $-3.32M | $94.00K | (m) | (m) | -35.29× | Reported |
| 2013-09-30 | (m) | $1.88M | (m) | $-3.56M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $2.07M | (m) | $-3.81M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $1.79M | (m) | $-3.99M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $1.81M | (m) | $-3.33M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $1.93M | (m) | $-2.86M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $1.73M | (m) | $-2.43M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $2.07M | (m) | $-2.22M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $2.21M | (m) | $-2.31M | $12.00K | (m) | (m) | -192.50× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $2.94M | (m) | $-1.89M | $15.00K | (m) | (m) | -125.93× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| SANUWAVE Health, Inc. (SNWV) | United States | $0.041B | 5.47 |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| InspireMD, Inc. (NSPR) | $0.033B | ||
| PAVmed Inc. (PAVM) | United States | $0.031B | -3.00 |
| Glucotrack, Inc. (GCTK) | United States | $0.027B | |
| ACCURAY INC (ARAY) | United States | $0.027B | -0.63 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 |